Last reviewed · How we verify
Rocklatan 0.02%-0.005% Ophthalmic Solution
Rocklatan 0.02%-0.005% Ophthalmic Solution is a Prostaglandin analog / Rho kinase inhibitor combination Small molecule drug developed by Eye Centers of Southeast Texas. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension.
Rocklatan combines a prostaglandin analog and a rho kinase inhibitor to reduce intraocular pressure through increased uveoscleral outflow and decreased aqueous humor production.
Rocklatan combines a prostaglandin analog and a rho kinase inhibitor to reduce intraocular pressure through increased uveoscleral outflow and decreased aqueous humor production. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Rocklatan 0.02%-0.005% Ophthalmic Solution |
|---|---|
| Sponsor | Eye Centers of Southeast Texas |
| Drug class | Prostaglandin analog / Rho kinase inhibitor combination |
| Target | Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Netarsudil, the rho kinase inhibitor component, increases conventional and uveoscleral outflow of aqueous humor and reduces aqueous humor production. Latanoprost, the prostaglandin F analog, further increases uveoscleral outflow. Together, these dual mechanisms provide additive intraocular pressure reduction in glaucoma and ocular hypertension patients.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation
- Corneal verticillata
- Increased iris pigmentation
- Eyelash growth
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (PHASE3)
- Next Generation Rocklatan (PHASE2)
- Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost (PHASE4)
- Rocklatan® Evaluation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rocklatan 0.02%-0.005% Ophthalmic Solution CI brief — competitive landscape report
- Rocklatan 0.02%-0.005% Ophthalmic Solution updates RSS · CI watch RSS
- Eye Centers of Southeast Texas portfolio CI
Frequently asked questions about Rocklatan 0.02%-0.005% Ophthalmic Solution
What is Rocklatan 0.02%-0.005% Ophthalmic Solution?
How does Rocklatan 0.02%-0.005% Ophthalmic Solution work?
What is Rocklatan 0.02%-0.005% Ophthalmic Solution used for?
Who makes Rocklatan 0.02%-0.005% Ophthalmic Solution?
What drug class is Rocklatan 0.02%-0.005% Ophthalmic Solution in?
What development phase is Rocklatan 0.02%-0.005% Ophthalmic Solution in?
What are the side effects of Rocklatan 0.02%-0.005% Ophthalmic Solution?
What does Rocklatan 0.02%-0.005% Ophthalmic Solution target?
Related
- Drug class: All Prostaglandin analog / Rho kinase inhibitor combination drugs
- Target: All drugs targeting Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK)
- Manufacturer: Eye Centers of Southeast Texas — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Compare: Rocklatan 0.02%-0.005% Ophthalmic Solution vs similar drugs
- Pricing: Rocklatan 0.02%-0.005% Ophthalmic Solution cost, discount & access